{
    "clinical_study": {
        "@rank": "149555", 
        "acronym": "XANAP", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This is an international observational study in patients with non-valvular atrial\n      fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent\n      stroke or non-central nervous system systemic embolism."
        }, 
        "brief_title": "Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Stroke"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female and male patients \u2265 18 years of age with a diagnosis of non-valvular atrial\n             fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS\n             (Central Nervous System) systemic embolism, and who consent to participate in the\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with a diagnosis of non-valvular atrial fibrillation who start treatment with\n        rivaroxaban to prevent stroke or non-CNS systemic embolism"
            }
        }, 
        "enrollment": {
            "#text": "2300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750788", 
            "org_study_id": "16371", 
            "secondary_id": "XA1205"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.", 
            "intervention_name": "Rivaroxaban (Xarelto, BAY59-7939)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Stroke", 
            "Embolism", 
            "Atrial Fibrillation"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Hong Kong"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "India"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Indonesia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Malaysia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Philippines"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Singapore"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Taiwan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Thailand"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Vietnam"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Hong Kong", 
                "India", 
                "Indonesia", 
                "Korea, Republic of", 
                "Malaysia", 
                "Philippines", 
                "Singapore", 
                "Taiwan", 
                "Thailand", 
                "Vietnam"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Xarelto\u00ae on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "India: Drugs Controller General of India", 
                "Indonesia: National Agency of Drug and Food Control", 
                "Indonesia: Ethics Committee", 
                "Korea: Food and Drug Administration", 
                "Korea: Institutional Review Board", 
                "Malaysia: Institutional Review Board", 
                "Pakistan: Research Ethics Committee", 
                "Philippines : Food and Drug Administration", 
                "Singapore: Domain Specific Review Boards", 
                "Singapore: Health Sciences Authority", 
                "Taiwan: Institutional Review Board", 
                "Thailand: Food and Drug Administration", 
                "Thailand: Ministry of Public Health", 
                "Vietnam: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Adjudicated major bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"
            }, 
            {
                "measure": "Safety variables will be summarized using descriptive statistics based on adverse events collection", 
                "safety_issue": "Yes", 
                "time_frame": "after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "All cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"
            }, 
            {
                "measure": "Adjudicated symptomatic thromboembolic events", 
                "safety_issue": "Yes", 
                "time_frame": "after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}